PMDA drug package insert
ヘパリンNa透析用150単位/mLシリンジ20mL「フソー」
PMDA Prescription drug · 扶桑薬品工業株式会社 · package insert Oct 1, 2026
Key facts
| Brand names | ヘパリンNa透析用150単位/mLシリンジ20mL「フソー」, ヘパリンNa透析用200単位/mLシリンジ20mL「フソー」, ヘパリンNa透析用250単位/mLシリンジ20mL「フソー」, ヘパリンNa透析用350単位/mLシリンジ20mL「フソー」 |
|---|---|
| Nonproprietary names | ヘパリンナトリウム |
| Companies | 製造販売元／扶桑薬品工業株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 血液凝固阻止剤 |
| Therapeutic category codes | 873334 |
| YJ codes | 3334402G8034, 3334402P1030, 3334402P2044, 3334402P3024 |
| Approval numbers | 21900AMX00531, 21800AMZ10232, 21800AMZ10231, 22100AMX02215 |
| Package insert edition | 第4版 |
| Package insert date | Oct 1, 2026 |
| PMDA document key | 670156_3334402G8034_1 |
| PMDA company code | 670156 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: